U-PVCT

Q:PVCT - PROVECTUS BIOPHARMACEUTICALS INC - https://www.pvct.com

04:31:28 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
PVCT - Q	not subscribed					0.0734	+0.0034	4.9	40.1	2	11	0.0737 0.0737 0.07	0.1517 0.0607	11:21:56	Oct 09	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
OTC Markets Indicators -- Primary Market: OTC Markets -- Tier: OTCQB -- Status: Active

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Portfolio

Recent Trades - Last 10 of 11

More trades...

Time ET	Ex	Price	Change	Volume
11:21:56	Q	0.0734	0.0034	275
11:21:56	Q	0.07282	0.00282	275
09:50:08	Q	0.0719	0.0019	2,200
09:50:08	Q	0.07365	0.00365	300
09:42:24	Q	0.07		1,000
09:42:24	Q	0.07145	0.00145	1,000
09:35:17	Q	0.0737	0.0037	15,000
09:35:17	Q	0.07		15,000
09:33:52	Q	0.07148	0.00148	3,000
09:30:02	Q	0.0737	0.0037	1,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2025-10-09 08:00	U:PVCT	News Release200	Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
2025-09-29 08:00	U:PVCT	News Release200	Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
2025-06-26 08:00	U:PVCT	News Release200	Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer
2025-06-09 08:00	U:PVCT	News Release200	Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders
2025-01-14 08:00	U:PVCT	News Release200	Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs
2024-12-11 09:00	U:PVCT	News Release200	Provectus Biopharmaceuticals Launches VisiRose, Provectus's Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology

Date ET

Symbol

Type

Headline

2025-10-09 08:00

U:PVCT

News Release

Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy

2025-09-29 08:00

U:PVCT

News Release

Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer